GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Middle East Pharmaceutical Industries Co (SAU:4016) » Definitions » Debt-to-EBITDA

Middle East Pharmaceutical Industries Co (SAU:4016) Debt-to-EBITDA : 2.18 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Middle East Pharmaceutical Industries Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Middle East Pharmaceutical Industries Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ﷼73.6 Mil. Middle East Pharmaceutical Industries Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ﷼0.0 Mil. Middle East Pharmaceutical Industries Co's annualized EBITDA for the quarter that ended in Sep. 2024 was ﷼33.7 Mil. Middle East Pharmaceutical Industries Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 2.18.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Middle East Pharmaceutical Industries Co's Debt-to-EBITDA or its related term are showing as below:

SAU:4016' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.23
Current: 2.23

During the past 0 years, the highest Debt-to-EBITDA Ratio of Middle East Pharmaceutical Industries Co was 2.23. The lowest was 0.00. And the median was 0.00.

SAU:4016's Debt-to-EBITDA is ranked worse than
57.57% of 674 companies
in the Drug Manufacturers industry
Industry Median: 1.62 vs SAU:4016: 2.23

Middle East Pharmaceutical Industries Co Debt-to-EBITDA Historical Data

The historical data trend for Middle East Pharmaceutical Industries Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Middle East Pharmaceutical Industries Co Debt-to-EBITDA Chart

Middle East Pharmaceutical Industries Co Annual Data
Trend
Debt-to-EBITDA

Middle East Pharmaceutical Industries Co Quarterly Data
Jun23 Sep23 Jun24 Sep24
Debt-to-EBITDA - - - 2.18

Competitive Comparison of Middle East Pharmaceutical Industries Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Middle East Pharmaceutical Industries Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Middle East Pharmaceutical Industries Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Middle East Pharmaceutical Industries Co's Debt-to-EBITDA falls into.


;
;

Middle East Pharmaceutical Industries Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Middle East Pharmaceutical Industries Co's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Middle East Pharmaceutical Industries Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(73.582 + 0) / 33.716
=2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Middle East Pharmaceutical Industries Co  (SAU:4016) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Middle East Pharmaceutical Industries Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Middle East Pharmaceutical Industries Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Middle East Pharmaceutical Industries Co Business Description

Traded in Other Exchanges
N/A
Address
8146 King Muhammad V, Sulaimaniyah, P.O. Box 4180, Riyadh, SAU, 11491
Website
Middle East Pharmaceutical Industries Co is a holding company is engaged in manufacturing medicines, medicated and non-medicated creams and gels.

Middle East Pharmaceutical Industries Co Headlines

No Headlines